This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

NU1618

Nuon Therapeutics, Inc.

Drug Names(s): tranilast and allopurinol

Description: NU1618 is a combination of tranilast and allopurinol. Allopurinol reduces the production or uric acid through inhibition of the enzyme xanthine oxidase. The company says that tranilast inhibits uric acid transport by both URAT1 and GLUT9, transporters in the kidney that regulate uric acid excretion from the body. Tranilast has anti-inflammatory properties and inhibits collagen synthesis, so is approved for asthma and keloid/scars in Japan. As an immune system modulator, it may address the chronic inflammatory component of gout.


NU1618 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug